Back to Index
Leslie Ballas, MD
Assistant Professor of Clinical Radiation Oncology
Radiation Oncology
NOR G350 1441 EASTLAKE AVE Health Sciences Campus Los Angeles
+1 323 865 3050


After residency, I spent time on the faculty at MD Anderson Cancer Center treating hematologic malignancies (leukemia, lymphoma and multiple myeloma). I have considerable experience treating this patient population. Because many lymphomas are highly curable, management of long term side effects from treatment is essential. I have used many different treatment techniques and modalities to minimize radiation dose to normal structures, thereby minimizing late effects from treatment. I also have a great deal of experience working with cutaneous lymphomas and the management of this category of lymphomas.

Dr. Leslie Ballas also specializes in cancers of the genitourinary tract, including malignancies of the prostate, urinary bladder, testicle, and kidney. Her research has focused on improving quality of life for men with prostate cancer. She is involved in the development of cancer treatment clinical trials for patients with genitourinary cancers. And has brought multiple genitourinary cooperative group studies to USC. Dr. Ballas’ interests include advanced technology integration into cancer therapeutics, including image-guide radiation therapy (IGRT), stereotactic body radiotherapy (SBRT), and intensity modulated radiotherapy (IMRT).


Current Management Strategy for Penile Cancer and Future Directions. Curr Oncol Rep. 2017 Aug; 19(8):54. View in: PubMed

Prostate-Specific Antigen and Prostate-Specific Antigen Kinetics in Predicting 18F-Sodium Fluoride Positron Emission Tomography-Computed Tomography Positivity for First Bone Metastases in Patients with Biochemical Recurrence after Radical Prostatectomy. World J Nucl Med. 2017 Jul-Sep; 16(3):229-236. View in: PubMed

Immunotherapy in urothelial cancer, part 2: adjuvant, neoadjuvant, and adjunctive treatment. Clin Adv Hematol Oncol. 2017 Jul; 15(7):543-551. View in: PubMed

Immunotherapy in urothelial cancer, part 1: T-cell checkpoint inhibition in advanced or metastatic disease. Clin Adv Hematol Oncol. 2017 Jun; 15(6):466-477. View in: PubMed

Tolerance of Orthotopic Ileal Neobladders to Radiotherapy: A Multi-institutional Retrospective Study. Clin Genitourin Cancer. 2017 May 10. View in: PubMed

The Rationale for Post-Operative Radiation in Localized Bladder Cancer. Bladder Cancer. 2017 Jan 27; 3(1):19-30. View in: PubMed

ACR Appropriateness Criteria® Hodgkin Lymphoma-Favorable Prognosis Stage I and II. Am J Clin Oncol. 2016 Dec; 39(6):535-544. View in: PubMed

What Medical, Urologic, and Radiation Oncologists Want from Molecular Imaging of Prostate Cancer. J Nucl Med. 2016 Oct; 57(Suppl 3):6S-12S. View in: PubMed

Maternal and Fetal Outcomes After Therapy for Hodgkin or Non-Hodgkin Lymphoma Diagnosed During Pregnancy. JAMA Oncol. 2016 Aug 01; 2(8):1065-9. View in: PubMed

ACR Appropriateness Criteria® Recurrent Hodgkin Lymphoma. Oncology (Williston Park). 2016 12 15; 30(12):1099-103, 1106-8. View in: PubMed

Radical Prostatectomy or External Beam Radiation Therapy vs No Local Therapy for Survival Benefit in Metastatic Prostate Cancer: A SEER-Medicare Analysis. J Urol. 2015 Aug; 194(2):378-85. View in: PubMed

Modern radiotherapeutic strategies in the management of lymphoma. Future Oncol. 2015; 11(6):1011-20. View in: PubMed

Chromoplexy and hypoxic microenvironment drives prostate cancer. Lancet Oncol. 2014 Dec; 15(13):1419-21. View in: PubMed

Emergence of integrated urology-radiation oncology practices in the State of Texas. Int J Radiat Oncol Biol Phys. 2012 Sep 01; 84(1):15-9. View in: PubMed

Involved field radiation for Hodgkin's lymphoma: the actual dose to breasts in close proximity. Med Dosim. 2012; 37(4):374-82. View in: PubMed

Cytogenetic profile of patients with acute myeloid leukemia and central nervous system disease. Cancer. 2012 Jan 01; 118(1):112-7. View in: PubMed

Advances in radiobiological studies using a microbeam. J Radiat Res. 2009 Mar; 50 Suppl A:A7-A12. View in: PubMed

Radiation therapy facilities in the United States. Int J Radiat Oncol Biol Phys. 2006 Nov 15; 66(4):1204-11. View in: PubMed

Amelioration of vascular dysfunctions in diabetic rats by an oral PKC beta inhibitor. Science. 1996 May 03; 272(5262):728-31. View in: PubMed

Powered bySC CTSI